PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
6390595-0	1984	[Effect of chlorpropamide on insulin levels of patients with diabetes type II].	Chlorpropamide	11-25	insulin	Homo sapiens	29-36
6369456-0	1984	Blood glucose and serum C-peptide after a single chlorpropamide dose.	Chlorpropamide	49-63	insulin	Homo sapiens	24-33
6363239-5	1983	The chlorpropamide-responsive patients presented higher insulin levels after the glucose challenge and a lower hepatic insulin extraction than the non-responsive ones.	Chlorpropamide	4-18	insulin	Homo sapiens	56-63
6341151-3	1983	Following oral glucose (50 g), the chlorpropamide-alcohol flush positive diabetic patients with complications had a lower serum insulin and higher blood glycerol than the other three groups.	Chlorpropamide	35-49	insulin	Homo sapiens	128-135
6313759-1	1983	To determine vasopressin (VP)-potentiating effect of chlorpropamide (CPMD), we studied the effect of CPMD in vivo and in vitro in kidneys and in specific tubule segments of rats with hypothalamic diabetes insipidus, homozygotes of the Brattleboro strain (DI rats).	Chlorpropamide	53-67	arginine vasopressin	Rattus norvegicus	26-28
6958470-0	1982	Further studies on the mechanism by which chlorpropamide alters the action of vasopressin.	Chlorpropamide	42-56	arginine vasopressin	Rattus norvegicus	78-89
6958470-1	1982	The injection of chlorpropamide into Brattleboro homozygous rats (di/di) has previously been shown to result in enhanced activation of renal medullary adenylate cyclase activity and increased renal medullary content of cAMP in response to 1-desamino-8-D-arginine vasopressin (dDAVP).	Chlorpropamide	17-31	arginine vasopressin	Rattus norvegicus	263-274
6958470-7	1982	These observations support the concept that in vivo chlorpropamide acts at the receptor of the vasopressin-sensitive part of the tubule to augment responsiveness to vasopressin.	Chlorpropamide	52-66	arginine vasopressin	Rattus norvegicus	95-106
6958470-7	1982	These observations support the concept that in vivo chlorpropamide acts at the receptor of the vasopressin-sensitive part of the tubule to augment responsiveness to vasopressin.	Chlorpropamide	52-66	arginine vasopressin	Rattus norvegicus	165-176
6814965-0	1982	High density lipoprotein cholesterol and apolipoprotein a-1 concentrations in non-insulin dependent diabetics treated by diet and chlorpropamide.	Chlorpropamide	130-144	apolipoprotein A1	Homo sapiens	41-59
6855871-0	1983	Test for chlorpropamide-alcohol flush becomes positive after prolonged chlorpropamide treatment in insulin-dependent and non-insulin-dependent diabetics.	Chlorpropamide	9-23	insulin	Homo sapiens	99-106
6855871-0	1983	Test for chlorpropamide-alcohol flush becomes positive after prolonged chlorpropamide treatment in insulin-dependent and non-insulin-dependent diabetics.	Chlorpropamide	9-23	insulin	Homo sapiens	125-132
6855871-0	1983	Test for chlorpropamide-alcohol flush becomes positive after prolonged chlorpropamide treatment in insulin-dependent and non-insulin-dependent diabetics.	Chlorpropamide	71-85	insulin	Homo sapiens	99-106
7045153-3	1982	The percent change in basal insulin correlated with the pretreatment FPG (r = 0.62; P less than 0.01) and inversely with the change in FPG during chlorpropamide (r = -0.57; P less than 0.025).	Chlorpropamide	146-160	insulin	Homo sapiens	28-35
6759222-3	1982	We studied 11 patients with IDDM to determine whether chlorpropamide acts directly on the insulin receptor and whether it could augment the effect of insulin on glycemic control.	Chlorpropamide	54-68	insulin	Homo sapiens	90-97
7249936-2	1981	He received propranolol and insulin without subsequent problems; however, when the insulin was changed to chlorpropamide, a significant increase in blood sugar occurred.	Chlorpropamide	106-120	insulin	Homo sapiens	83-90
6295230-0	1982	Use of the Brattleboro rat in studies of the mechanism by which chlorpropamide enhances the action of vasopressin.	Chlorpropamide	64-78	arginine vasopressin	Rattus norvegicus	102-113
6269688-3	1981	After chlorpropamide all patients showed a rise in met-enkephalin concentrations from a basal level of 50 +/- 7.2 ng/l to a peak of 75 +/- 8.1 ng/l (p less than 0.001).	Chlorpropamide	6-20	proopiomelanocortin	Homo sapiens	51-65
6269688-6	1981	In six normal subjects pretreated with chlorpropamide the met-enkephalin concentration also rose from a basal level of 72 +/- 15 ng/l to a peak of 103 +/- 9.4 ng/l (p less than 0.002).	Chlorpropamide	39-53	proopiomelanocortin	Homo sapiens	58-72
7464556-0	1981	Chlorpropamide effect: measurement of neurophysin and vasopressin in humans and rats.	Chlorpropamide	0-14	arginine vasopressin	Homo sapiens	54-65
7464556-6	1981	Levels of neurophysin in the pituitaries of rats showed no change in rats given chlorpropamide, while the content of vasopressin was increased, possibly indicating a chronic decreased secretion of vasopressin in rats given chlorpropamide.	Chlorpropamide	223-237	arginine vasopressin	Rattus norvegicus	117-128
7464556-6	1981	Levels of neurophysin in the pituitaries of rats showed no change in rats given chlorpropamide, while the content of vasopressin was increased, possibly indicating a chronic decreased secretion of vasopressin in rats given chlorpropamide.	Chlorpropamide	223-237	arginine vasopressin	Rattus norvegicus	197-208
435952-2	1979	The mean Hb A1 concentration at presentation in 16 patients treated with chlorpropamide was significantly higher than that in 12 patients treated with insulin, and the duration of glycaemic symptoms was much longer in the chlorpropamide-treated group.	Chlorpropamide	73-87	hemoglobin subunit alpha 1	Homo sapiens	9-14
7428798-1	1980	Serum chlorpropamide concentrations (s-CPA) were determined and related to clinical findings in 83 outpatients with maturity onset diabetes.	Chlorpropamide	6-20	carboxypeptidase A1	Homo sapiens	39-42
6243558-0	1980	Augmentation by chlorpropamide of 1-deamino-8-D-arginine vasopressin-induced antidiuresis and stimulation of renal medullary adenylate cyclase and accumulation of adenosine 3",5"-monophosphate.	Chlorpropamide	16-30	arginine vasopressin	Rattus norvegicus	57-68
7418103-0	1980	Nuclear magnetic resonance study of the binding of tolbutamide and chlorpropamide to bovine serum albumin.	Chlorpropamide	67-81	albumin	Homo sapiens	92-105
478080-11	1979	These findings may be explained by an extrapancreatic effect of the drug or by an indirect result of chlorpropamide induced insulin release which occured earlier in the course of therapy.	Chlorpropamide	101-115	insulin	Homo sapiens	124-131
435952-2	1979	The mean Hb A1 concentration at presentation in 16 patients treated with chlorpropamide was significantly higher than that in 12 patients treated with insulin, and the duration of glycaemic symptoms was much longer in the chlorpropamide-treated group.	Chlorpropamide	222-236	hemoglobin subunit alpha 1	Homo sapiens	9-14
199621-0	1977	Inhibition of vasopressin-stimulated prostaglandin E biosynthesis by chlorpropamide in the toad urinary bladder.	Chlorpropamide	69-83	arginine vasopressin	Homo sapiens	14-25
199621-2	1977	Chlorpropamide is known to enhance the water permeability response of the toad urinary bladder to vasopressin and to theophylline.	Chlorpropamide	0-14	arginine vasopressin	Homo sapiens	98-109
199621-4	1977	In this study, the effect of chlorpropamide on vasopressin-, theophylline-, and cyclic AMP-stimulated water flow and on prostaglandin E biosynthesis was investigated in the toad urinary bladder in vitro.	Chlorpropamide	29-43	arginine vasopressin	Homo sapiens	47-58
199621-5	1977	Chlorpropamide inhibited prostaglandin E biosynthesis during vasopressin-, theophylline- and cyclic AMP-stimulated water flow.	Chlorpropamide	0-14	arginine vasopressin	Homo sapiens	61-72
411723-1	1977	The blood glucose and plasma insulin response to the two hypoglycaemic agents, chlorpropamide (Diabenese) and glibenclamide (Daonil) was determined in normal subjects under strict metabolic control in a double blind study.	Chlorpropamide	79-93	insulin	Homo sapiens	29-36
411723-1	1977	The blood glucose and plasma insulin response to the two hypoglycaemic agents, chlorpropamide (Diabenese) and glibenclamide (Daonil) was determined in normal subjects under strict metabolic control in a double blind study.	Chlorpropamide	95-104	insulin	Homo sapiens	29-36
913926-0	1977	Plasma insulin and glucose levels in maturity onset diabetics treated with chlorpropamide.	Chlorpropamide	75-89	insulin	Homo sapiens	7-14
913926-3	1977	Blood glucose concentration was highest and the plasma insulin concentration lowest in patients taking the largest dose of chlorpropamide.	Chlorpropamide	123-137	insulin	Homo sapiens	55-62
913926-4	1977	Patients on a small daily dose of chlorpropamide were well controlled and had higher than normal insulin levels.	Chlorpropamide	34-48	insulin	Homo sapiens	97-104
865282-0	1977	Comparison of clofibrate and chlorpropamide in vasopressin-responsive diabetes insipidus.	Chlorpropamide	29-43	arginine vasopressin	Homo sapiens	47-58
175653-4	1976	Treatment with chlorpropamide (one to three months, average dose equals 375 mg/day) was associated with a marked reduction in hyperglycemia and an increase toward normal in insulin binding to mononuclear cells.	Chlorpropamide	15-29	insulin	Homo sapiens	173-180
836992-0	1977	Potentiation of the response to vasopressin (pitressin) by treatment with a combination of chlorpropamide and chlorothiazide in Brattleboro rats with hereditary hypothalamic diabetes insipidus.	Chlorpropamide	91-105	arginine vasopressin	Rattus norvegicus	32-43
836992-4	1977	3 The daily administration of 5 mg chlorpropamide combined with chlorothiazide in the drinking water (4 mg/1) to Pitressin-treated DI rats potentiated the response to small doses of vasopressin (25 and 50 mu Pitressin/24 hours).	Chlorpropamide	35-49	arginine vasopressin	Rattus norvegicus	182-193
1188549-5	1975	Chlorpropamide treatment reduced the insulin requirement to zero, which was unrelated to a change in insulin antibody concentration.	Chlorpropamide	0-14	insulin	Homo sapiens	37-44
1192687-10	1975	It is suggested that the antidiuretic action of chlorpropamide, carbamazepine and clofibrate is localized at the receptor site for ADH in the distal renal tubular cell.	Chlorpropamide	48-62	arginine vasopressin	Homo sapiens	131-134
1192687-0	1975	Paradoxical diuresis after vasopressin administration to patients with neurohypophyseal diabetes insipidus treated with chlorpropamide, carbamazepine or clofibrate.	Chlorpropamide	120-134	arginine vasopressin	Homo sapiens	27-38
175514-0	1975	Chlorpropamide-induced inhibition of serum calcium, urinary calcium, and cyclic AMP responses to parathyroid hormone.	Chlorpropamide	0-14	parathyroid hormone	Homo sapiens	97-116
169346-0	1975	Effect of chlorpropamide on renal response to parathyroid hormone in normal subjects and in patients with hypoparathyroidism and pseudohypoparathyroidism.	Chlorpropamide	10-24	parathyroid hormone	Homo sapiens	46-65
169346-1	1975	Chlorpropamide inhibited by 35 to 65% the increase in the urinary excretion of adenosine 3",5"-monophosphate (cyclic AMP) following a large dose (250 U) of parathyroid hormone (PTH) in normal subjects and patients with hypoparathyroidism and pseudohypoparathyroidism.	Chlorpropamide	0-14	parathyroid hormone	Homo sapiens	156-175
4698246-0	1973	Evidence for a role of antidiuretic hormone (ADH) in the antidiuretic action of chlorpropamide.	Chlorpropamide	80-94	arginine vasopressin	Homo sapiens	23-43
4851417-0	1974	Diurnal variations of serum insulin, total glucagon, cortisol, glucose and free fatty acids in normal and diabetic subjects before and after treatment with chlorpropamide.	Chlorpropamide	156-170	insulin	Homo sapiens	28-35
4717441-4	1973	Though intravenous glucose tolerance deteriorates between the second and third trimesters in women with no features of diabetes, a significant improvement occurs after a course of chlorpropamide in a daily dosage of 100 mg during pregnancy in chemical diabetes, but this treatment did not enhance the rate of return to normal glucose tolerance post partum.Plasma glucose and insulin studies showed no evidence of hypoglycaemia or hyperinsulinism in the mother at delivery or in the newborn when chlorpropamide had been used compared with a group receiving no such treatment.	Chlorpropamide	180-194	insulin	Homo sapiens	375-382
4820657-0	1974	Insulin secretion in patients with diabetes insipidus during long-term treatment with chlorpropamide.	Chlorpropamide	86-100	insulin	Homo sapiens	0-7
4698246-0	1973	Evidence for a role of antidiuretic hormone (ADH) in the antidiuretic action of chlorpropamide.	Chlorpropamide	80-94	arginine vasopressin	Homo sapiens	45-48
5039189-0	1972	The combined effect of chlorpropamide and chlorothiazide upon the response to vasopressin (Pitressin) in rats with hereditary diabetes insipidus.	Chlorpropamide	23-37	arginine vasopressin	Rattus norvegicus	78-89
4197367-0	1973	[Plasma insulin and glucose levels in diabetics treated with glibenclamide and chlorporpamide].	Chlorpropamide	79-93	insulin	Homo sapiens	8-15
5037076-0	1972	The combined effect of chlorpropamide and chlorothiazide upon the response to vasopressin (Pitressin) in rats with hereditary diabetes insipidus.	Chlorpropamide	23-37	arginine vasopressin	Rattus norvegicus	78-89
4257741-0	1971	[Participation of the antidiuretic hormone (ADH) in the activity of chlorpropamide on water metabolism, in toads].	Chlorpropamide	68-82	arginine vasopressin	Homo sapiens	22-42
4631986-0	1972	Clinical observations on the mechanism of the antidiuretic action of chlorpropamide in vasopressin-sensitive diabetes insipidus and in normal subjects.	Chlorpropamide	69-83	arginine vasopressin	Homo sapiens	87-98
5563815-1	1971	Chlorpropamide was found to be an effective antidiuretic agent in vasopressin-sensitive diabetes insipidus.	Chlorpropamide	0-14	arginine vasopressin	Homo sapiens	66-77
5134293-0	1971	Effect of phenformin and chlorpropamide on renin activity in the rat.	Chlorpropamide	25-39	renin	Rattus norvegicus	43-48
4257741-0	1971	[Participation of the antidiuretic hormone (ADH) in the activity of chlorpropamide on water metabolism, in toads].	Chlorpropamide	68-82	arginine vasopressin	Homo sapiens	44-47
5435243-0	1970	Potentiation of vasopressin action by chlorpropamide in vivo.	Chlorpropamide	38-52	arginine vasopressin	Homo sapiens	16-27
5435244-0	1970	Potentiation of the antidiuretic effect of vasopressin by chlorpropamide.	Chlorpropamide	58-72	arginine vasopressin	Homo sapiens	43-54
5773412-0	1969	Treatment of vasopressin-sensitive diabetes insipidus with chlorpropamide.	Chlorpropamide	59-73	arginine vasopressin	Homo sapiens	13-24
5426161-0	1970	[Chlorpropamide, tolbutamide and saluretics in the treatment of diabetes insipidus sensitive to vasopressin].	Chlorpropamide	1-15	arginine vasopressin	Homo sapiens	96-107
4868334-0	1968	The pattern of rsponse of plasma insulin and glucose to meals and fasting during chlorpropamide therapy.	Chlorpropamide	81-95	insulin	Homo sapiens	33-40
4303530-0	1969	Effect of chlorpropamide on the permeability of the urinary bladder of the toad and the response to vasopressin, adenosine-3",5"-monophosphate and theophylline.	Chlorpropamide	10-24	arginine vasopressin	Homo sapiens	100-111
6041638-0	1967	The influence of chlorpropamide pre-treatment on insulin and growth hormone release after arginine.	Chlorpropamide	17-31	insulin	Homo sapiens	49-56
6028757-0	1967	Effect of chlorpropamide on serum glucose and immunoreactive insulin concentrations in patients with maturity-onset diabetes mellitus.	Chlorpropamide	10-24	insulin	Homo sapiens	61-68
5223515-0	1966	Role of various tissues in chlorpropamide potentiation of the insulin effect.	Chlorpropamide	27-41	insulin	Homo sapiens	62-69
5883129-12	1965	Attempts to advance the time at which glucokinase first appears by infusions of glucose, insulin and chlorpropamide alone and in various combinations have resulted in marginal effects only.	Chlorpropamide	101-115	glucokinase	Rattus norvegicus	38-49
5879941-0	1965	[The role of various tissues in chlorpropamide potentiation of the insulin effect].	Chlorpropamide	32-46	insulin	Homo sapiens	67-74
13913279-0	1961	Chlorpropamide in patients on high insulin dosage.	Chlorpropamide	0-14	insulin	Homo sapiens	35-42
6041638-0	1967	The influence of chlorpropamide pre-treatment on insulin and growth hormone release after arginine.	Chlorpropamide	17-31	growth hormone 1	Homo sapiens	61-75
31925653-1	2020	Binding strength of the anti-diabetic drugs chlorpropamide (CPM) and tolbutamide (TBM) with model protein bovine serum albumin (BSA) shows strong modulation in presence of colloidal gold nanoparticles (AuNP).	Chlorpropamide	44-58	albumin	Homo sapiens	113-126
4700049-0	1973	A paradoxical effect of chlorpropamide on the plasma glucose and immunoreactive insulin response to intravenous glucose in normal dogs.	Chlorpropamide	24-38	insulin	Canis lupus familiaris	80-87
32702468-6	2020	Monotherapy-failure occurred in 72%-82%-75% and 79% for those randomised to chlorpropamide-glibenclamide-basal insulin or metformin respectively-after median 4.5 (3.0-6.6)-3.7 (2.6-5.6)-4.2 (2.7-6.5) and 3.8 (2.6- 5.2) years.	Chlorpropamide	76-90	insulin	Homo sapiens	111-118
31925653-1	2020	Binding strength of the anti-diabetic drugs chlorpropamide (CPM) and tolbutamide (TBM) with model protein bovine serum albumin (BSA) shows strong modulation in presence of colloidal gold nanoparticles (AuNP).	Chlorpropamide	60-63	albumin	Homo sapiens	113-126
25393056-1	2015	The crystal structure and vibrational spectra of the chlorpropamide have been studied by means of the X-ray diffraction and Raman spectroscopy at pressures up to 24.6 and 4.4 GPa, respectively.	Chlorpropamide	53-67	glycophorin A (MNS blood group)	Homo sapiens	175-178
30205233-0	2018	Chromatographic studies of chlorpropamide interactions with normal and glycated human serum albumin based on affinity microcolumns.	Chlorpropamide	27-41	albumin	Homo sapiens	86-99
25393056-3	2015	At pressures above 9.6 GPa, a transformation to the amorphous phase of chlorpropamide was revealed.	Chlorpropamide	71-85	glycophorin A (MNS blood group)	Homo sapiens	23-26
15842554-7	2005	In in vivo clinical trials, eight subjects with the CYP2C9*1/*3 genotype exhibited significantly lower nonrenal clearance [*1/*3 vs.*1/*1: 1.8 +/- 0.2 vs. 2.4 +/- 0.1 ml h(-1) kg(-1), P < 0.05; 95% confidence interval (CI) on the difference 0.2, 1.0] and higher metabolic ratios (of chlorpropamide/2-OH-chlorpropamide in urine: *1/*3 vs.*1/*1: 1.01 +/- 0.19 vs. 0.56 +/- 0.08, P < 0.05; 95% CI on the difference - 0.9, - 0.1) than did 13 subjects with CYP2C9*1/*1 genotype.	Chlorpropamide	286-300	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	52-58
22886551-7	2012	These indicate a long-range haplotype containing the CYP2C9*13 and CYP2C19*2 mutation, which means most CYP2C9*13 carriers will carry the CYP2C19*2 allele and the six SNPs of the CYP2C9*1B haplotype group, and may have more reduced intrinsic clearance of drugs such as phenytoin, tolbutamide and chlorpropamide that are metabolized by both CYP2C9 and CYP2C19.	Chlorpropamide	296-310	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	53-59
22886551-7	2012	These indicate a long-range haplotype containing the CYP2C9*13 and CYP2C19*2 mutation, which means most CYP2C9*13 carriers will carry the CYP2C19*2 allele and the six SNPs of the CYP2C9*1B haplotype group, and may have more reduced intrinsic clearance of drugs such as phenytoin, tolbutamide and chlorpropamide that are metabolized by both CYP2C9 and CYP2C19.	Chlorpropamide	296-310	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	67-74
22886551-7	2012	These indicate a long-range haplotype containing the CYP2C9*13 and CYP2C19*2 mutation, which means most CYP2C9*13 carriers will carry the CYP2C19*2 allele and the six SNPs of the CYP2C9*1B haplotype group, and may have more reduced intrinsic clearance of drugs such as phenytoin, tolbutamide and chlorpropamide that are metabolized by both CYP2C9 and CYP2C19.	Chlorpropamide	296-310	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	104-110
22886551-7	2012	These indicate a long-range haplotype containing the CYP2C9*13 and CYP2C19*2 mutation, which means most CYP2C9*13 carriers will carry the CYP2C19*2 allele and the six SNPs of the CYP2C9*1B haplotype group, and may have more reduced intrinsic clearance of drugs such as phenytoin, tolbutamide and chlorpropamide that are metabolized by both CYP2C9 and CYP2C19.	Chlorpropamide	296-310	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	138-145
22886551-7	2012	These indicate a long-range haplotype containing the CYP2C9*13 and CYP2C19*2 mutation, which means most CYP2C9*13 carriers will carry the CYP2C19*2 allele and the six SNPs of the CYP2C9*1B haplotype group, and may have more reduced intrinsic clearance of drugs such as phenytoin, tolbutamide and chlorpropamide that are metabolized by both CYP2C9 and CYP2C19.	Chlorpropamide	296-310	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	104-110
22886551-7	2012	These indicate a long-range haplotype containing the CYP2C9*13 and CYP2C19*2 mutation, which means most CYP2C9*13 carriers will carry the CYP2C19*2 allele and the six SNPs of the CYP2C9*1B haplotype group, and may have more reduced intrinsic clearance of drugs such as phenytoin, tolbutamide and chlorpropamide that are metabolized by both CYP2C9 and CYP2C19.	Chlorpropamide	296-310	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	104-110
22886551-7	2012	These indicate a long-range haplotype containing the CYP2C9*13 and CYP2C19*2 mutation, which means most CYP2C9*13 carriers will carry the CYP2C19*2 allele and the six SNPs of the CYP2C9*1B haplotype group, and may have more reduced intrinsic clearance of drugs such as phenytoin, tolbutamide and chlorpropamide that are metabolized by both CYP2C9 and CYP2C19.	Chlorpropamide	296-310	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	138-145
15842554-0	2005	Chlorpropamide 2-hydroxylation is catalysed by CYP2C9 and CYP2C19 in vitro: chlorpropamide disposition is influenced by CYP2C9, but not by CYP2C19 genetic polymorphism.	Chlorpropamide	0-14	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	47-53
15842554-0	2005	Chlorpropamide 2-hydroxylation is catalysed by CYP2C9 and CYP2C19 in vitro: chlorpropamide disposition is influenced by CYP2C9, but not by CYP2C19 genetic polymorphism.	Chlorpropamide	0-14	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	58-65
15842554-0	2005	Chlorpropamide 2-hydroxylation is catalysed by CYP2C9 and CYP2C19 in vitro: chlorpropamide disposition is influenced by CYP2C9, but not by CYP2C19 genetic polymorphism.	Chlorpropamide	0-14	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	120-126
17725854-7	2007	We also assessed e-NOS expression (using polymerase chain reaction after reverse transcription of mRNAs into cDNAs) and NOS activity (conversion of L-arginine to citrulline) in the mesenteric vascular bed of chlorpropamide-treated n-STZ, vehicle-treated n-STZ, and control rats.	Chlorpropamide	208-222	nitric oxide synthase 3	Rattus norvegicus	17-22
15842554-7	2005	In in vivo clinical trials, eight subjects with the CYP2C9*1/*3 genotype exhibited significantly lower nonrenal clearance [*1/*3 vs.*1/*1: 1.8 +/- 0.2 vs. 2.4 +/- 0.1 ml h(-1) kg(-1), P < 0.05; 95% confidence interval (CI) on the difference 0.2, 1.0] and higher metabolic ratios (of chlorpropamide/2-OH-chlorpropamide in urine: *1/*3 vs.*1/*1: 1.01 +/- 0.19 vs. 0.56 +/- 0.08, P < 0.05; 95% CI on the difference - 0.9, - 0.1) than did 13 subjects with CYP2C9*1/*1 genotype.	Chlorpropamide	286-300	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	458-464
15842554-0	2005	Chlorpropamide 2-hydroxylation is catalysed by CYP2C9 and CYP2C19 in vitro: chlorpropamide disposition is influenced by CYP2C9, but not by CYP2C19 genetic polymorphism.	Chlorpropamide	76-90	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	47-53
15842554-0	2005	Chlorpropamide 2-hydroxylation is catalysed by CYP2C9 and CYP2C19 in vitro: chlorpropamide disposition is influenced by CYP2C9, but not by CYP2C19 genetic polymorphism.	Chlorpropamide	76-90	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	58-65
15842554-0	2005	Chlorpropamide 2-hydroxylation is catalysed by CYP2C9 and CYP2C19 in vitro: chlorpropamide disposition is influenced by CYP2C9, but not by CYP2C19 genetic polymorphism.	Chlorpropamide	76-90	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	120-126
15842554-1	2005	AIMS: We evaluated the involvement of cytochrome P450 (CYP) isoforms 2C9 and 2C19 in chlorpropamide 2-hydroxylation in vitro and in chlorpropamide disposition in vivo.	Chlorpropamide	85-99	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	38-53
15842554-1	2005	AIMS: We evaluated the involvement of cytochrome P450 (CYP) isoforms 2C9 and 2C19 in chlorpropamide 2-hydroxylation in vitro and in chlorpropamide disposition in vivo.	Chlorpropamide	85-99	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	55-58
15842554-2	2005	METHODS: To identify CYP isoforms(s) that catalyse 2-hydroxylation of chlorpropamide, the incubation studies were conducted using human liver microsomes and recombinant CYP isoforms.	Chlorpropamide	70-84	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	21-24
15842554-2	2005	METHODS: To identify CYP isoforms(s) that catalyse 2-hydroxylation of chlorpropamide, the incubation studies were conducted using human liver microsomes and recombinant CYP isoforms.	Chlorpropamide	70-84	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	169-172
15842554-3	2005	To evaluate whether genetic polymorphisms of CYP2C9 and/or CYP2C19 influence the disposition of chlorpropamide, a single oral dose of 250 mg chlorpropamide was administered to 21 healthy subjects pregenotyped for CYP2C9 and CYP2C19.	Chlorpropamide	96-110	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	45-51
15842554-9	2005	CONCLUSIONS: These results suggest that chlorpropamide disposition is principally determined by CYP2C9 activity in vivo, although both CYP2C9 and CYP2C19 have a catalysing activity of chlorpropamide 2-hydroxylation pathway.	Chlorpropamide	40-54	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	96-102
15842554-9	2005	CONCLUSIONS: These results suggest that chlorpropamide disposition is principally determined by CYP2C9 activity in vivo, although both CYP2C9 and CYP2C19 have a catalysing activity of chlorpropamide 2-hydroxylation pathway.	Chlorpropamide	184-198	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	135-141
15842554-9	2005	CONCLUSIONS: These results suggest that chlorpropamide disposition is principally determined by CYP2C9 activity in vivo, although both CYP2C9 and CYP2C19 have a catalysing activity of chlorpropamide 2-hydroxylation pathway.	Chlorpropamide	184-198	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	146-153
15318096-3	2004	A mechanism of CPAF has been regarded as the inhibition of aldehyde dehydrogenase 2 (ALDH2) by an N-alkyl-substituted derivative of chlorpropamide, and the expression of these mutations of ALDH2 and alcohol dehydrogenase 2 (ADH2) could determine the alcohol tolerance among the Japanese population.	Chlorpropamide	132-146	aldehyde dehydrogenase 2 family member	Homo sapiens	59-83
15642492-9	2005	Quantitative RT-PCR studies showed that, compared with the control islets, cells preincubated with glibenclamide or chlorpropamide had an increased expression of insulin mRNA, with no change in the expression of GLUT-1.	Chlorpropamide	116-130	insulin	Homo sapiens	162-169
15318096-3	2004	A mechanism of CPAF has been regarded as the inhibition of aldehyde dehydrogenase 2 (ALDH2) by an N-alkyl-substituted derivative of chlorpropamide, and the expression of these mutations of ALDH2 and alcohol dehydrogenase 2 (ADH2) could determine the alcohol tolerance among the Japanese population.	Chlorpropamide	132-146	aldehyde dehydrogenase 2 family member	Homo sapiens	85-90
15318096-3	2004	A mechanism of CPAF has been regarded as the inhibition of aldehyde dehydrogenase 2 (ALDH2) by an N-alkyl-substituted derivative of chlorpropamide, and the expression of these mutations of ALDH2 and alcohol dehydrogenase 2 (ADH2) could determine the alcohol tolerance among the Japanese population.	Chlorpropamide	132-146	alcohol dehydrogenase 1B (class I), beta polypeptide	Homo sapiens	224-228
12222701-3	2002	If this disease could be diagnosed earlier, therapy with chlorpropamide, doxorubicin, vincristine and prednisone (CHOP) could bring about a remission (2,3,4).	Chlorpropamide	57-71	DNA damage inducible transcript 3	Homo sapiens	114-118
12060057-6	2002	We exemplify the method using HbA1c levels from data from patients on chlorpropamide (n = 64) or glibenclamide (n = 65) monotherapy in the Oxford cohort of the UKPDS.	Chlorpropamide	70-84	hemoglobin subunit alpha 1	Homo sapiens	30-34
11672702-0	2001	Inhibition of ALDH3A1-catalyzed oxidation by chlorpropamide analogues.	Chlorpropamide	45-59	aldehyde dehydrogenase 3 family member A1	Homo sapiens	14-21
10807592-0	2000	Chlorpropamide upregulates antidiuretic hormone receptors and unmasks constitutive receptor signaling.	Chlorpropamide	0-14	arginine vasopressin	Homo sapiens	27-47
11306038-0	2001	Inhibition of ALDH3A1-catalyzed oxidation by chlorpropamide analogues.	Chlorpropamide	45-59	aldehyde dehydrogenase 3 family member A1	Homo sapiens	14-21
10854830-2	2000	Uptake of p-aminohippurate via rOAT1 was markedly inhibited by glibenclamide and nateglinide, and moderately by chlorpropamide and tolbutamide.	Chlorpropamide	112-126	solute carrier family 22 member 6	Rattus norvegicus	31-36
7777712-0	1995	[Response of insulin and C-peptide to a mixed meal in non-insulin-dependent diabetics treated with insulin and chlorpropamide].	Chlorpropamide	111-125	insulin	Homo sapiens	13-20
9884422-1	1999	To elucidate whether sulfonylureas directly influence renin secretion, the effect of tolbutamide, glibenclamide, or chlorpropamide on renin secretion was investigated by using the perfused kidney of the rat.	Chlorpropamide	116-130	renin	Rattus norvegicus	134-139
9884422-3	1999	Renin activity significantly increased from a basal value of 11.7 +/- 3.6 to a peak value of 20.6 +/- 5.5 ng/Ang I/ml/h with tolbutamide, from 14.4 +/- 4.6 to 32.7 +/- 6.5 ng/Ang I/ml/h with glibenclamide, and from 15.0 +/- 4.9 to 30.4 +/- 6.1 ng/Ang I/ml/h with chlorpropamide.	Chlorpropamide	263-277	renin	Rattus norvegicus	0-5
12893455-6	1996	The results showed that chlorpropamide, like disulfiram, produced a higher blood AcH level consistent with a greater inhibition of the low-Km mitochondrial ALDH in the UChA rats than in the UChB rats.	Chlorpropamide	24-38	aldehyde dehydrogenase 3 family, member A1	Rattus norvegicus	156-160
7777712-0	1995	[Response of insulin and C-peptide to a mixed meal in non-insulin-dependent diabetics treated with insulin and chlorpropamide].	Chlorpropamide	111-125	insulin	Homo sapiens	25-34
7777712-4	1995	We therefore designed a prospective study combining insulin and chloropropamide in order to evaluate any improvement in insulin response to a standardized meal load and a consequent amelioration of glucose control.	Chlorpropamide	64-79	insulin	Homo sapiens	120-127
7990120-6	1994	These results suggest that latent alkyl isocyanates are inhibitors of AlDH, giving further support to the hypothesis that the inhibition of AlDH in vivo by the hypoglycemic agent chlorpropamide may be due to the release of n-propyl isocyanate following metabolic bioactivation.	Chlorpropamide	179-193	aldehyde dehydrogenase 3 family, member A1	Rattus norvegicus	70-74
7990120-2	1994	N1-Allylchlorpropamide 3 was, as expected, a potent inhibitor of hepatic AlDH in rats, as indicated by the 4-fold increase in the levels of ethanol-derived blood acetaldehyde relative to that elicited by chlorpropamide itself.	Chlorpropamide	8-22	aldehyde dehydrogenase 3 family, member A1	Rattus norvegicus	73-77
7990120-6	1994	These results suggest that latent alkyl isocyanates are inhibitors of AlDH, giving further support to the hypothesis that the inhibition of AlDH in vivo by the hypoglycemic agent chlorpropamide may be due to the release of n-propyl isocyanate following metabolic bioactivation.	Chlorpropamide	179-193	aldehyde dehydrogenase 3 family, member A1	Rattus norvegicus	140-144
1362115-7	1992	In conclusion, 1) NIDDM patients treated with chlorpropamide showed higher fasting insulin levels with 46.4% of them meeting the criteria for chronic hyperinsulinemia; 2) female gender, uric acid, BMI and triglyceride were the risk factors correlated with chronic hyperinsulinemia; and 3) the presence of diabetic complications and diabetic control correlated poorly with chronic hyperinsulinemia.	Chlorpropamide	46-60	insulin	Homo sapiens	83-90
1360512-3	1992	The efficacy of chlorpropamide in alloxan-diabetic rabbits after intravenous injection (150 mumol kg-1) was less than that in normal rabbits as measured by the serum insulin levels, and the efficacy did not change when the dose was increased.	Chlorpropamide	16-30	insulin	Oryctolagus cuniculus	166-173
1360512-4	1992	However, compensation of serum Ca2+ levels in alloxan-diabetic rabbits caused an increase in the efficacy of chlorpropamide observed as an increase in serum insulin and a decrease in serum glucose levels.	Chlorpropamide	109-123	insulin	Oryctolagus cuniculus	157-164
8507452-0	1993	Hypertension secondary to chlorpropamide with amelioration by changing to insulin.	Chlorpropamide	26-40	insulin	Homo sapiens	74-81
8507452-3	1993	In 10 patients in whom insulin was reinstituted, systolic BP fell significantly (P < .005), suggesting that in type II diabetics chlorpropamide exerts a relative hypertensive effect in comparison to insulin.	Chlorpropamide	132-146	insulin	Homo sapiens	23-30
1421649-13	1992	ACE inhibitors may be a predisposing factor for CPA-induced hyponatremia.	Chlorpropamide	48-51	angiotensin I converting enzyme	Homo sapiens	0-3
1409040-9	1992	The change of Tolbutamide or Chlorpropamide to Gliclazide increased the therapeutical efficacy only in these patients, in whom such a change was associated with an increase of prandial, reactive serum insulin level (IRI).	Chlorpropamide	29-43	insulin	Homo sapiens	201-208
1540248-0	1992	Failure of glutathione and cysteine prodrugs to block the chlorpropamide-induced inhibition of aldehyde dehydrogenase in vivo.	Chlorpropamide	58-72	aldehyde dehydrogenase 3 family, member A1	Rattus norvegicus	95-117
1756685-3	1991	Using estimates of drug utilization based on a defined daily dose, hospitalization rates were 5.8 per 1000 PY (95% CI 4.4-7.6) for chlorpropamide, 16.0 per 1000 PY (95% CI 9.5-26.9) for glyburide, and 9.1 per 1000 PY (95% CI 6.9-11.9) for insulin.	Chlorpropamide	131-145	insulin	Homo sapiens	239-246
1930902-5	1991	The test is specific for albumin failing to cross react with other plasma proteins present in urine, as well as with glibenclamide, chlorpropamide, phenformin, hemoglobin, glucose, urea and thymol.	Chlorpropamide	132-146	albumin	Homo sapiens	25-32
1797318-9	1991	Chlorpropamide potentiated ADH-induced water flow, in keeping with the hypothesis that chlorpropamide sensitizes the renal tubules to ADH-induced water flow.	Chlorpropamide	87-101	arginine vasopressin	Homo sapiens	134-137
1797318-9	1991	Chlorpropamide potentiated ADH-induced water flow, in keeping with the hypothesis that chlorpropamide sensitizes the renal tubules to ADH-induced water flow.	Chlorpropamide	0-14	arginine vasopressin	Homo sapiens	27-30
1797318-9	1991	Chlorpropamide potentiated ADH-induced water flow, in keeping with the hypothesis that chlorpropamide sensitizes the renal tubules to ADH-induced water flow.	Chlorpropamide	0-14	arginine vasopressin	Homo sapiens	134-137
1797318-9	1991	Chlorpropamide potentiated ADH-induced water flow, in keeping with the hypothesis that chlorpropamide sensitizes the renal tubules to ADH-induced water flow.	Chlorpropamide	87-101	arginine vasopressin	Homo sapiens	27-30
34955900-8	2021	Previous studies have also shown that the V2R has a role in chlorpropamide-induced hyponatremia.	Chlorpropamide	60-74	arginine vasopressin receptor 2	Homo sapiens	42-45
2274021-2	1990	In patients with reduced circulating levels of vasopressin, chlorpropamide, clofibrate, idroclorotiazide etc., enhance the effect of vasopressin on the renal tubule or induce a release of vasopressin, thus reducing the diuresis.	Chlorpropamide	60-74	arginine vasopressin	Homo sapiens	133-144
2274021-2	1990	In patients with reduced circulating levels of vasopressin, chlorpropamide, clofibrate, idroclorotiazide etc., enhance the effect of vasopressin on the renal tubule or induce a release of vasopressin, thus reducing the diuresis.	Chlorpropamide	60-74	arginine vasopressin	Homo sapiens	133-144
3295472-8	1987	These studies demonstrate that the sulfonylurea, chlorpropamide, stimulates glucose transport and potentiates insulin"s effect on this process by acting at a site(s) beyond insulin receptor binding and phosphorylation.	Chlorpropamide	49-63	insulin receptor	Rattus norvegicus	173-189
2657066-0	1989	N1-alkyl-substituted derivatives of chlorpropamide as inhibitors of aldehyde dehydrogenase.	Chlorpropamide	36-50	aldehyde dehydrogenase 3 family, member A1	Rattus norvegicus	68-90
2657066-1	1989	On the basis of an earlier observation that the N1-ethyl derivative of the hypoglycemic agent chlorpropamide (CP) inhibited aldehyde dehydrogenase (AlDH) in rats without producing hypoglycemia, we undertook a structure-activity study to assess the effect of altering the alkyl substituents at N1 and N3, as well as substituting O for N at the latter position, and evaluated these analogues for their effect on AlDH in vivo and in vitro.	Chlorpropamide	94-108	aldehyde dehydrogenase 3 family, member A1	Rattus norvegicus	124-146
2657066-1	1989	On the basis of an earlier observation that the N1-ethyl derivative of the hypoglycemic agent chlorpropamide (CP) inhibited aldehyde dehydrogenase (AlDH) in rats without producing hypoglycemia, we undertook a structure-activity study to assess the effect of altering the alkyl substituents at N1 and N3, as well as substituting O for N at the latter position, and evaluated these analogues for their effect on AlDH in vivo and in vitro.	Chlorpropamide	94-108	aldehyde dehydrogenase 3 family, member A1	Rattus norvegicus	148-152
2657066-1	1989	On the basis of an earlier observation that the N1-ethyl derivative of the hypoglycemic agent chlorpropamide (CP) inhibited aldehyde dehydrogenase (AlDH) in rats without producing hypoglycemia, we undertook a structure-activity study to assess the effect of altering the alkyl substituents at N1 and N3, as well as substituting O for N at the latter position, and evaluated these analogues for their effect on AlDH in vivo and in vitro.	Chlorpropamide	94-108	aldehyde dehydrogenase 3 family, member A1	Rattus norvegicus	410-414
2707308-0	1989	Chlorpropamide alters AVP-receptor binding of rat renal tubular membranes.	Chlorpropamide	0-14	arginine vasopressin	Rattus norvegicus	22-25
2707308-2	1989	Our data indicate that chlorpropamide alters AVP-receptor binding in a competitive manner.	Chlorpropamide	23-37	arginine vasopressin	Rattus norvegicus	45-48
3276184-3	1988	The world"s literature was reviewed for other cases of chlorpropamide toxicity in which insulin levels have been measured during hypoglycemia.	Chlorpropamide	55-69	insulin	Homo sapiens	88-95
3312441-6	1987	Alternatively, chlorpropamide and antidiuretic hormone may inhibit renin release by increasing chloride delivery to the loop.	Chlorpropamide	15-29	renin	Homo sapiens	67-72
3623414-0	1987	Effect of short- and long-term chlorpropamide therapy on oral glucose tolerance and erythrocyte insulin receptors in non-obese non-insulin dependent diabetes mellitus.	Chlorpropamide	31-45	insulin	Homo sapiens	96-103
3535793-5	1986	Both glibenclamide and chlorpropamide stimulated insulin release from HIT-T15 cells.	Chlorpropamide	23-37	insulin	Mesocricetus auratus	49-56
3769401-0	1986	Chlorpropamide-alcohol flush reaction and isoenzyme profiles of alcohol dehydrogenase and aldehyde dehydrogenase.	Chlorpropamide	0-14	aldo-keto reductase family 1 member A1	Homo sapiens	64-85
3769401-1	1986	To investigate the enzymatic basis of the chlorpropamide-alcohol flush reaction (CPAF) we compared the isoenzyme profiles of alcohol dehydrogenase (ADH) and aldehyde dehydrogenase (ALDH) from liver biopsies, and of ALDH alone from erythrocytes and leucocytes, in CPAF-positive and CPAF-negative subjects.	Chlorpropamide	42-56	aldo-keto reductase family 1 member A1	Homo sapiens	125-146
3535793-7	1986	Only chlorpropamide significantly potentiated glucose induced insulin release.	Chlorpropamide	5-19	insulin	Mesocricetus auratus	62-69
2951157-2	1986	Chlorpropamide was found to have a generalized cholesterol lowering effect (progressive significant fall in mean total cholesterol, LDL-C, HDL-C, and HDL3-C) with no significant change in the ratio of high-density lipoprotein to low-density lipoprotein cholesterol which was independent of insulin secretion.	Chlorpropamide	0-14	HDL3	Homo sapiens	150-154
3967624-2	1985	Chlorpropamide treatment significantly depressed basal phosphorylase a activity and lessened the increments in the activity of this enzyme induced by 10(-10) -10(-8) M glucagon and arginine vasopressin.	Chlorpropamide	0-14	arginine vasopressin	Rattus norvegicus	190-201
3935120-2	1985	Both drugs increased serum insulin for more than 8 h but less than 24 h. The effect of glibenclamide was slightly stronger than that of chlorpropamide.	Chlorpropamide	136-150	insulin	Homo sapiens	27-34